Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia

作者：Advani Anjali S^*; Gundacker Holly M; Sala Torra Olga; Radich Jerald P; Lai Raymond; Slovak Marilyn L; Lancet Jeffrey E; Coutre Steve E; Stuart Robert K; Mims Martha P; Stiff Patrick J; Appelbaum Frederick R

来源：British Journal of Haematology, 2010, 151(5): 430-434.

DOI：10.1111/j.1365-2141.2010.08387.x

• clofarabine
• cytarabine
• acute lymphocytic leukaemia
• relapse
• prognosis

P>Clofarabine and cytarabine target different steps in DNA synthesis and replication, are synergistic in vivo, and have non-overlapping toxicities, making this combination a potentially promising treatment for acute lymphocytic leukaemia. Thirty-seven patients were treated. The median age was 41 years, 44% of patients were either in >= 2nd relapse or had refractory disease and 59% of patients had poor risk cytogenetics. Six out of 36 patients (17%) achieved a complete remission with or without complete count recovery; median overall survival was 3 months. Nucleoside transporter expression did not predict outcome. This regimen lacked sufficient activity to warrant further testing.

• 出版日期2010-12